

Solange Peters

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2592160/publications.pdf>

Version: 2024-02-01

205
papers

25,467
citations

14614

66
h-index

7718

150
g-index

208
all docs

208
docs citations

208
times ranked

26796
citing authors

#	ARTICLE	IF	CITATIONS
1	First-Line Nivolumab in Stage IV or Recurrent Nonâ€“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 2415-2426.	13.9	2,145
2	Nivolumab plus Ipilimumab in Advanced Nonâ€“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2020-2031.	13.9	1,866
3	Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Nonâ€“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 829-838.	13.9	1,858
4	Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. <i>Annals of Oncology</i> , 2019, 30, 44-56.	0.6	1,742
5	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , 2020, 395, 1907-1918.	6.3	1,395
6	Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 563-580.	12.5	1,235
7	First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2021, 397, 375-386.	6.3	638
8	Brain metastases. <i>Nature Reviews Disease Primers</i> , 2019, 5, 5.	18.1	579
9	Lung Cancer That Harbors an <i>HER2</i> Mutation: Epidemiologic Characteristics and Therapeutic Perspectives. <i>Journal of Clinical Oncology</i> , 2013, 31, 1997-2003.	0.8	572
10	COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. <i>Lancet Oncology, The</i> , 2020, 21, 914-922.	5.1	503
11	Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Nonâ€“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 661.	3.4	446
12	2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014, 25, 1462-1474.	0.6	410
13	Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 2369-2379.	0.8	410
14	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1â€“Selected Advanced Nonâ€“Small-Cell Lung Cancer (BIRCH). <i>Journal of Clinical Oncology</i> , 2017, 35, 2781-2789.	0.8	348
15	Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. <i>Annals of Oncology</i> , 2020, 31, 1056-1064.	0.6	337
16	Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Nonâ€“Small Cell Lung Cancer in the Global Phase III ALEX Study. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1233-1243.	0.5	324
17	Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. <i>Lancet, The</i> , 2015, 386, 1049-1056.	6.3	316
18	2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. <i>Annals of Oncology</i> , 2015, 26, 1573-1588.	0.6	308

#	ARTICLE	IF	CITATIONS
19	MET: a promising anticancer therapeutic target. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 314-326.	12.5	275
20	Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. <i>Lancet Oncology</i> , The, 2020, 21, 645-654.	5.1	247
21	Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. <i>Annals of Oncology</i> , 2014, 25, 1681-1690.	0.6	246
22	Alectinib versus crizotinib in treatment-naïve anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. <i>Annals of Oncology</i> , 2018, 29, 2214-2222.	0.6	243
23	Scientific Advances in Lung Cancer 2015. <i>Journal of Thoracic Oncology</i> , 2016, 11, 613-638.	0.5	231
24	Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCOâ€“ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. <i>Annals of Oncology</i> , 2019, 30, 171-210.	0.6	214
25	2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. <i>Annals of Oncology</i> , 2014, 25, 1475-1484.	0.6	210
26	Overcoming therapy resistance in EGFR-mutant lung cancer. <i>Nature Cancer</i> , 2021, 2, 377-391.	5.7	198
27	COVID-19 and Cancer: Current Challenges and Perspectives. <i>Cancer Cell</i> , 2020, 38, 629-646.	7.7	196
28	Definition of Synchronous Oligometastatic Nonâ€“Small Cell Lung Cancerâ€“A Consensus Report. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2109-2119.	0.5	189
29	The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. <i>Cancer Treatment Reviews</i> , 2016, 45, 139-162.	3.4	187
30	The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2017, 12, 194-207.	0.5	186
31	Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2018, 36, 3007-3014.	0.8	184
32	SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Nonâ€“Small-Cell Lung Cancerâ€“A Multicenter Single-Arm Phase II Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2872-2880.	0.8	183
33	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1409-1424.	0.5	182
34	Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. <i>Lancet Respiratory Medicine</i> , the, 2017, 5, 435-444.	5.2	172
35	Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1651-1658.	5.1	170
36	Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project. <i>Journal of Clinical Oncology</i> , 2014, 32, 2780-2787.	0.8	163

#	ARTICLE	IF	CITATIONS
37	Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. <i>Clinical Cancer Research</i> , 2019, 25, 64-72.	3.2	159
38	Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. <i>Lung Cancer</i> , 2019, 134, 127-140.	0.9	156
39	ALK inhibitors in the treatment of advanced NSCLC. <i>Cancer Treatment Reviews</i> , 2014, 40, 300-306.	3.4	152
40	New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. <i>Lancet Oncology</i> , The, 2019, 20, e54-e64.	5.1	149
41	Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. <i>Journal of Clinical Oncology</i> , 2021, 39, 1349-1359.	0.8	147
42	Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1451-1457.	0.5	141
43	Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug-drug interactions. <i>Cancer Treatment Reviews</i> , 2014, 40, 917-926.	3.4	134
44	Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations. <i>Journal of Thoracic Oncology</i> , 2021, 16, 764-773.	0.5	128
45	Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. <i>Cancer Treatment Reviews</i> , 2014, 40, 716-722.	3.4	123
46	Optimizing panel-based tumor mutational burden (TMB) measurement. <i>Annals of Oncology</i> , 2019, 30, 1496-1506.	0.6	123
47	Gender medicine and oncology: report and consensus of an ESMO workshop. <i>Annals of Oncology</i> , 2019, 30, 1914-1924.	0.6	120
48	Polymorphism of HIV Type 1 Gag p7/p1 and p1/p6 Cleavage Sites: Clinical Significance and Implications for Resistance to Protease Inhibitors. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1209-1213.	0.5	117
49	Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression. <i>Clinical Cancer Research</i> , 2013, 19, 5749-5757.	3.2	113
50	Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. <i>Cancer Discovery</i> , 2020, 10, 1514-1527.	7.7	108
51	Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIb non-small-cell lung cancer: a multicentre phase II trial. <i>Lancet Oncology</i> , The, 2009, 10, 785-793.	5.1	106
52	Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). <i>Journal of Thoracic Oncology</i> , 2019, 14, 1086-1094.	0.5	99
53	Dramatic Response Induced by Vemurafenib in a BRAF V600E-Mutated Lung Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2013, 31, e341-e344.	0.8	98
54	Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. , 2020, 8, e000604.		98

#	ARTICLE	IF	CITATIONS
55	ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer. ESMO Open, 2020, 5, e000820.	2.0	96
56	Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. ESMO Open, 2016, 1, e000142.	2.0	95
57	PD-1 blockade in advanced NSCLC: A focus on pembrolizumab. Cancer Treatment Reviews, 2018, 62, 39-49.	3.4	94
58	Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies. Journal of Clinical Oncology, 2022, 40, 598-610.	0.8	94
59	Challenges in lung cancer therapy during the COVID-19 pandemic. Lancet Respiratory Medicine, the, 2020, 8, 542-544.	5.2	88
60	Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic. Journal of Thoracic Oncology, 2020, 15, 1119-1136.	0.5	82
61	Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14). Journal of Thoracic Oncology, 2021, 16, 278-288.	0.5	82
62	How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. Annals of Oncology, 2019, 30, 884-896.	0.6	78
63	Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 2691-2698.	3.2	78
64	Severity of COVID-19 in patients with lung cancer: evidence and challenges. , 2021, 9, e002266.		78
65	BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1396-1403.	0.5	76
66	Resistance to Nucleoside Analog Reverse Transcriptase Inhibitors Mediated by Human Immunodeficiency Virus Type 1 p6 Protein. Journal of Virology, 2001, 75, 9644-9653.	1.5	73
67	Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03). European Journal of Cancer, 2012, 48, 377-384.	1.3	73
68	A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study. Clinical Cancer Research, 2021, 27, 1631-1640.	3.2	70
69	Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts. Journal of Thoracic Oncology, 2019, 14, 1935-1947.	0.5	69
70	Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. European Journal of Cancer, 2019, 109, 28-35.	1.3	69
71	Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program. Journal of Thoracic Oncology, 2018, 13, 1897-1905.	0.5	68
72	Nongenetic Evolution Drives Lung Adenocarcinoma Spatial Heterogeneity and Progression. Cancer Discovery, 2021, 11, 1490-1507.	7.7	67

#	ARTICLE	IF	CITATIONS
73	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscope Project. <i>Journal of Thoracic Oncology</i> , 2018, 13, 413-425.	0.5	66
74	GLUT1 Expression in Tumor-Associated Neutrophils Promotes Lung Cancer Growth and Resistance to Radiotherapy. <i>Cancer Research</i> , 2021, 81, 2345-2357.	0.4	65
75	Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients. <i>Melanoma Research</i> , 2008, 18, 220-224.	0.6	63
76	18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1859-1868.	3.3	62
77	Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). <i>Annals of Oncology</i> , 2019, 30, 161-165.	0.6	60
78	Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscope project. <i>Lung Cancer</i> , 2017, 111, 143-149.	0.9	57
79	Neutrophils in the era of immune checkpoint blockade. , 2021, 9, e002242.		52
80	Targeted therapy in NSCLC driven by HER2 insertions. <i>Translational Lung Cancer Research</i> , 2014, 3, 84-8.	1.3	52
81	Analysis of Natural Variants of the Human Immunodeficiency Virus Type 1 gag-pol Frameshift Stem-Loop Structure. <i>Journal of Virology</i> , 2002, 76, 7868-7873.	1.5	51
82	TERAVOLT: Thoracic Cancers International COVID-19 Collaboration. <i>Cancer Cell</i> , 2020, 37, 742-745.	7.7	51
83	Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey. <i>ESMO Open</i> , 2018, 3, e000422.	2.0	50
84	Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients. <i>JAMA Oncology</i> , 2022, 8, e220446.	3.4	48
85	The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer. <i>Cancer Cell</i> , 2020, 37, 738-741.	7.7	46
86	Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9043-9043.	0.8	45
87	Apnea-like suppression of respiratory motion: First evaluation in radiotherapy. <i>Radiotherapy and Oncology</i> , 2016, 118, 220-226.	0.3	43
88	COVID-19 and Cancer. <i>JAMA Oncology</i> , 2021, 7, 1882.	3.4	42
89	Immunotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 1986-1988.	13.9	40
90	A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscope Project. <i>Lung Cancer</i> , 2019, 131, 95-103.	0.9	40

#	ARTICLE	IF	CITATIONS
91	A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma. <i>Onc Immunology</i> , 2021, 10, 1860586.	2.1	40
92	Gender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer. <i>ESMO Open</i> , 2020, 5, e000796.	2.0	38
93	Preanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 756-767.	1.2	37
94	Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project. <i>Journal of Thoracic Oncology</i> , 2021, 16, 990-1002.	0.5	37
95	Immune Checkpoint Inhibitors in the Management of Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 682-695.	1.8	35
96	Report on the status of women occupying leadership roles in oncology. <i>ESMO Open</i> , 2018, 3, e000423.	2.0	35
97	Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence. <i>Cancer Cell</i> , 2020, 38, 624-625.	7.7	35
98	A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1647-1656.	0.5	34
99	Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival.. <i>Journal of Clinical Oncology</i> , 2020, 38, LBA1111-LBA1111.	0.8	34
100	Survey of the Impact of COVID-19 on Oncologists'™ Decision Making in Cancer. <i>JCO Global Oncology</i> , 2020, 6, 1248-1257.	0.8	33
101	Lungscape: Resected Non-™Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1675-1684.	0.5	31
102	Treatment and detection of ALK-rearranged NSCLC. <i>Lung Cancer</i> , 2013, 81, 145-154.	0.9	30
103	VeriStrat™ has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528. <i>Lung Cancer</i> , 2013, 79, 59-64.	0.9	30
104	Targeting KRAS-Mutant Non-™Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations. <i>Journal of Clinical Oncology</i> , 2020, 38, 4208-4218.	0.8	30
105	⁶⁸ Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis. , 2021, 9, e003594.		30
106	Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer. <i>Lung Cancer</i> , 2019, 138, 79-87.	0.9	29
107	The METeoric rise of MET in lung cancer. <i>Cancer</i> , 2020, 126, 4826-4837.	2.0	29
108	Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 259-268.	0.5	29

#	ARTICLE	IF	CITATIONS
109	Training in communication of oncology clinicians: a position paper based on the third consensus meeting among European experts in 2018. <i>Annals of Oncology</i> , 2018, 29, 2033-2036.	0.6	28
110	Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays TM and cross-validation with resections, in patients with, stage Iâ€”III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort. <i>Modern Pathology</i> , 2020, 33, 792-801.	2.9	28
111	Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement. <i>Lung Cancer</i> , 2020, 142, 114-119.	0.9	28
112	Low-Dose Vascular Photodynamic Therapy Decreases Tumor Interstitial Fluid Pressure, which Promotes Liposomal Doxorubicin Distribution in a Murine Sarcoma Metastasis Model. <i>Translational Oncology</i> , 2014, 7, 393-399.	1.7	27
113	SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)â€”A multicenter single-arm phase II trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9016-9016.	0.8	27
114	Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2040-2050.	0.5	26
115	Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced <i>ALK</i>+ Nonâ€”small Cell Lung Cancer in the Global Phase III ALEX Trial. <i>Clinical Cancer Research</i> , 2022, 28, 1800-1808.	3.2	26
116	Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8509-8509.	0.8	25
117	Relationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: a retrospective study. <i>ERJ Open Research</i> , 2020, 6, 00165-2019.	1.1	24
118	Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitorâ€”Related Cholangiohepatitis. <i>Journal of Thoracic Oncology</i> , 2021, 16, 318-326.	0.5	24
119	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1â€”Selected Advanced Nonâ€”Small-Cell Lung Cancer (BIRCH). <i>Journal of Clinical Oncology</i> , 2017, 35, 2781-2789.	0.8	24
120	Comparison of robust to standardized CT radiomics models to predict overall survival for nonâ€”small cell lung cancer patients. <i>Medical Physics</i> , 2020, 47, 4045-4053.	1.6	23
121	The CoVIDâ€”E risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVIDâ€”19. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2522-2532.	1.9	23
122	Targeting receptor activator of nuclear factor-kappa B as a new therapy for bone metastasis in non-small cell lung cancer. <i>Current Opinion in Oncology</i> , 2013, 25, 137-144.	1.1	22
123	Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 251-265.	2.0	22
124	Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient. , 2019, 7, 336.		21
125	Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). <i>Journal of Thoracic Oncology</i> , 2019, 14, 115-123.	0.5	21
126	Impact of an enhanced recovery after surgery pathway on thoracoscopic lobectomy outcomes in non-small cell lung cancer patients: a propensity score-matched study. <i>Translational Lung Cancer Research</i> , 2021, 10, 93-103.	1.3	21

#	ARTICLE	IF	CITATIONS
127	A single-arm phase II trial of afatinib in pretreated patients with advanced NSCLC harboring a <i>HER2</i> mutation: The ETOP NICHE trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9070-9070.	0.8	21
128	Genomic Features of Response to Combination Immunotherapy in Lung Cancer. <i>Cancer Cell</i> , 2018, 33, 791-793.	7.7	20
129	CheckMate 451: A randomized, double-blind, phase III trial of nivolumab (nivo), nivo plus ipilimumab (ipi), or placebo as maintenance therapy in patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC) after first-line platinum-based doublet chemotherapy (PT-DC).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS8579-TPS8579.	0.8	20
130	Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: The ETOP NICOLAS phase II trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8510-8510.	0.8	20
131	Targeting MET in EGFR resistance in non-small-cell lung cancer—ready for daily practice?. <i>Lancet Oncology</i> , 2020, 21, 320-322.	5.1	19
132	CheckMate 331: An open-label, randomized phase III trial of nivolumab versus chemotherapy in patients (pts) with relapsed small cell lung cancer (SCLC) after first-line platinum-based chemotherapy (PT-DC).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS8578-TPS8578.	0.8	19
133	RANKL Signaling Sustains Primary Tumor Growth in Genetically Engineered Mouse Models of Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2018, 13, 387-398.	0.5	18
134	Acceptance of the Advanced Practice Nurse in Lung Cancer Role by Healthcare Professionals and Patients: A Qualitative Exploration. <i>Journal of Nursing Scholarship</i> , 2018, 50, 540-548.	1.1	18
135	Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. <i>Lung Cancer</i> , 2020, 150, 90-96.	0.9	18
136	Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians. <i>ESMO Open</i> , 2020, 5, e001090.	2.0	18
137	Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced <i>ALK</i> + NSCLC.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9518-9518.	0.8	18
138	Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial. <i>Journal of Thoracic Oncology</i> , 2017, 12, 752-762.	0.5	17
139	Radiomics Feature Activation Maps as a New Tool for Signature Interpretability. <i>Frontiers in Oncology</i> , 2020, 10, 578895.	1.3	17
140	CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, e264-e268.	1.1	17
141	KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9001-9001.	0.8	17
142	Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient. <i>Melanoma Research</i> , 2014, 24, 496-500.	0.6	16
143	Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19).. <i>Journal of Clinical Oncology</i> , 2020, 38, LBA110-LBA110.	0.8	15
144	Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies. , 2022, 10, e003024.		15

#	ARTICLE	IF	CITATIONS
145	Feasibility of advanced practice nursing in lung cancer consultations during early treatment: A phase II study. <i>European Journal of Oncology Nursing</i> , 2017, 29, 106-114.	0.9	14
146	Patient and doctor perspectives on HIV screening in the emergency department: A prospective cross-sectional study. <i>PLoS ONE</i> , 2017, 12, e0180389.	1.1	14
147	Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 144, 10-19.	0.9	14
148	Afatinib in patients with metastatic <i>HER2</i> -mutant lung cancers: An international multicenter study. <i>Journal of Clinical Oncology</i> , 2017, 35, 9071-9071.	0.8	14
149	EORTC-1416-LCG/ETOP 8-15 "PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use. <i>Journal of Clinical Oncology</i> , 2022, 40, 8512-8512.	0.8	14
150	Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy. <i>Current Treatment Options in Oncology</i> , 2018, 19, 37.	1.3	13
151	Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2). <i>Clinical and Translational Science</i> , 2022, 15, 141-157.	1.5	13
152	Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel. <i>Journal of Clinical Oncology</i> , 2021, 39, e001882.		12
153	Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). <i>ESMO Open</i> , 2016, 1, e000107.	2.0	11
154	Preselection of robust radiomic features does not improve outcome modelling in non-small cell lung cancer based on clinical routine FDG-PET imaging. <i>EJNMMI Research</i> , 2021, 11, 79.	1.1	11
155	Targeting <i>HER2</i> -Mutant NSCLC "The Light Is On. <i>New England Journal of Medicine</i> , 2022, 386, 286-289.	13.9	11
156	The Promising Evolution of Targeted Therapeutic Strategies in Cancer. <i>Cancer Discovery</i> , 2021, 11, 810-814.	7.7	10
157	Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC). <i>Clinical Lung Cancer</i> , 2021, 22, 301-312.e8.	1.1	10
158	Patients' understanding of blood tests and attitudes to HIV screening in the emergency department of a Swiss teaching hospital: a cross-sectional observational study. <i>Swiss Medical Weekly</i> , 2015, 145, w14206.	0.8	10
159	A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry. <i>Journal of Thoracic Oncology</i> , 2022, 17, 661-674.	0.5	9
160	First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. <i>Lung Cancer</i> , 2022, 167, 8-16.	0.9	9
161	Describing adverse events in Swiss hospitalized oncology patients using the Global Trigger Tool. <i>Health Science Reports</i> , 2020, 3, e160.	0.6	8
162	Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab. <i>Clinical and Translational Radiation Oncology</i> , 2021, 27, 85-88.	0.9	8

#	ARTICLE	IF	CITATIONS
163	Imaging Features of Pulmonary Immune-related Adverse Events. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1449-1460.	0.5	8
164	Investigating Barriers in HIV-Testing Oncology Patients: The IBITOP Study, Phase I. <i>Oncologist</i> , 2016, 21, 1176-1182.	1.9	7
165	Delineating the Role of PD-1/PD-L1 Blockade in Advanced SCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1242-1244.	0.5	7
166	Appraising the Tail of the Survival Curve in the Era of PD-1/PD-L1 Checkpoint Blockade. <i>JAMA Oncology</i> , 2019, 5, 1403.	3.4	7
167	Optimizing Oral Targeted Anticancer Therapies Study for Patients With Solid Cancer: Protocol for a Randomized Controlled Medication Adherence Program Along With Systematic Collection and Modeling of Pharmacokinetic and Pharmacodynamic Data. <i>JMIR Research Protocols</i> , 2021, 10, e30090.	0.5	7
168	Early discharge after thoracoscopic anatomical pulmonary resection for non-small-cell lung cancer. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2021, 33, 892-898.	0.5	7
169	EORTC-ETOP randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with early stage non-small cell lung cancer (NSCLC) after resection and standard adjuvant chemotherapy: PEARLS (NCT02504372).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS8571-TPS8571.	0.8	7
170	Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital. <i>JCO Clinical Cancer Informatics</i> , 2022, , .	1.0	7
171	<i>EML4-ALK</i> Variant Affects <i>ALK</i> Resistance Mutations. <i>Journal of Clinical Oncology</i> , 2018, 36, 1257-1259.	0.8	6
172	Development and implementation strategies of a nurse-led symptom self-management program in outpatient cancer centres: The Symptom Navi [®] Programme. <i>European Journal of Oncology Nursing</i> , 2020, 44, 101714.	0.9	6
173	Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience. <i>Cancer Cell</i> , 2020, 38, 602-604.	7.7	6
174	Gender gap: surveying the world for tomorrow. <i>ESMO Open</i> , 2020, 5, e000805.	2.0	6
175	Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 1666-1678.	1.3	6
176	OncoAlert Round Table Discussions: The Global COVID-19 Experience. <i>JCO Global Oncology</i> , 2021, 7, 455-463.	0.8	6
177	Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy. <i>ESMO Open</i> , 2016, 1, e000118.	2.0	6
178	Treatment of pleural malignancies by photoinduction combined to systemic chemotherapy: Proof of concept on rodent lung tumors and feasibility study on porcine chest cavities. <i>Lasers in Surgery and Medicine</i> , 2015, 47, 807-816.	1.1	5
179	Emerging Options After Progression During Crizotinib Therapy. <i>Journal of Clinical Oncology</i> , 2016, 34, 643-645.	0.8	5
180	Implementation of the Symptom Navi [®] Programme for cancer patients in the Swiss outpatient setting: a study protocol for a cluster randomised pilot study (Symptom Navi [®] Pilot Study). <i>BMJ Open</i> , 2019, 9, e027942.	0.8	5

#	ARTICLE	IF	CITATIONS
181	Histological and Molecular Plasticity of ALK-positive Non-Small-Cell Lung Cancer under Targeted Therapy - a Case Report. <i>Journal of Physical Education and Sports Management</i> , 2022, , mcs.a006156.	0.5	5
182	How much platinum-based chemotherapy is enough in NSCLC?. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 8-10.	12.5	4
183	EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2019, 30, 1190-1192.	0.6	4
184	Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC – The ETOP/EORTC SPLENDOUR and AMGEN-249 trials. <i>Lung Cancer</i> , 2021, 161, 76-85.	0.9	4
185	Efficacy/safety of entrectinib in patients (pts) with ROS1-positive (ROS1+) advanced/metastatic NSCLC from the Blood First Assay Screening Trial (BFAST).. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA9023-LBA9023.	0.8	4
186	Investigating barriers in HIV-testing oncology patients. The IBITOP study: phase I. <i>Journal of the International AIDS Society</i> , 2014, 17, 19622.	1.2	3
187	Strength in numbers: predicting response to checkpoint inhibitors from large clinical datasets. <i>Cell</i> , 2021, 184, 571-573.	13.5	3
188	Treatment Decisions for Patients with Cancer during the COVID-19 Pandemic. <i>Cancer Discovery</i> , 2021, 11, 1330-1335.	7.7	3
189	Quantification of the spatial distribution of primary tumors in the lung to develop new prognostic biomarkers for locally advanced NSCLC. <i>Scientific Reports</i> , 2021, 11, 20890.	1.6	3
190	Long-lasting, irreversible and late-onset immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs): A real-world data analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15095-e15095.	0.8	3
191	Seeking New Approaches to Patients With Small Cell Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e477-e482.	1.8	2
192	Efficacy of targeted therapies for oncogene-driven lung cancer in early single-arm versus late phase randomized clinical trials: A comparative analysis. <i>Cancer Treatment Reviews</i> , 2022, 104, 102354.	3.4	2
193	Practical tips and tricks with recently approved molecular targeted agents in non-small-cell lung cancer. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 307-309.	2.2	1
194	Pan-HER inhibition in EGFR wild-type non-small-cell lung cancer. <i>Lancet Oncology, The</i> , 2014, 15, 1289-1290.	5.1	1
195	Primary Care-Led Transition Clinics Hold Promise in Improving Care Transitions for Cancer Patients Facing Social Disparities: A Commentary. <i>Journal of Primary Care and Community Health</i> , 2020, 11, 215013272095745.	1.0	1
196	Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases. <i>Frontiers in Oncology</i> , 2021, 11, 704295.	1.3	1
197	Design of ALTA-1L (ALK in lung cancer trial of brigatinib in first-line), a randomized phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)-naive patients (pts) with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS9098-TPS9098.	0.8	1
198	Setting the Benchmark for KRAS ^{G12C} -Mutated NSCLC. <i>New England Journal of Medicine</i> , 2022, 387, 180-183.	13.9	1

#	ARTICLE	IF	CITATIONS
199	RANKing lung cancer bone metastasis. Lung Cancer Management, 2012, 1, 87-90.	1.5	0
200	Effect of national HIV testing recommendations and local interventions on HIV testing practices in a Swiss university hospital: a retrospective analysis between 2012 and 2015. BMJ Open, 2018, 8, e021203.	0.8	0
201	Further molecular profiling of tumors harboring therapeutic targets within non-small cell lung cancer.. Journal of Clinical Oncology, 2014, 32, 8087-8087.	0.8	0
202	Molecular profiling of non-small cell lung cancer by histologic subtype.. Journal of Clinical Oncology, 2014, 32, 8057-8057.	0.8	0
203	Lung cancer patients with HER2 mutations treated with chemotherapy and HER2 targeted drugs: Results form the EUHER2 cohort study.. Journal of Clinical Oncology, 2015, 33, 11076-11076.	0.8	0
204	Randomized phase III trial of erlotinib vs. docetaxel in patients with advanced squamous cell non-small cell lung cancer (SqNSCLC) failing first line platinum based doublet chemotherapy stratified by VeriStrat Good vs VeriStrat Poor: The European Thoracic Oncology Platform (ETOP) EMPHASIS trial.. Journal of Clinical Oncology, 2015, 33, 8049-8049.	0.8	0
205	Delayed Diagnosis of Lung Carcinoma Presenting as Choroidal Metastasis in a COVID-19 Patient and Initially Treated with Osimertinib. Klinische Monatsblatter Fur Augenheilkunde, 2022, 239, 586-589.	0.3	0